Apr 14, 2016

Posted by in Biotech Stocks | 0 Comments

Investor’s Watch List: ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), Aegerion Pharmaceuticals Inc (NASDAQ:AEGR), Agenus Inc (NASDAQ:AGEN)

Investor’s Watch List: ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), Aegerion Pharmaceuticals Inc (NASDAQ:AEGR), Agenus Inc (NASDAQ:AGEN)

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) stock is at $33.22, up +3.04 percent from its previous close of $32.4. The stock opened the session at $32.56 and touched its highest price point at $33.31. The company’s stock’s lowest price point for the session stood at $31.82. Its yesterday’s volume was 2.74 million shares in comparison to its usual trading volume of 3.90 million shares.

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) on February 29, 2016 reported a net loss of $45.8 million, or $0.45 per common share, for the fourth quarter of 2015, compared to a net loss of $28.4 million, or $0.28 per common share, for the fourth quarter of 2014. The net losses for the fourth quarters of 2015 and 2014 included $8.9 million and $4.6 million, respectively, in non-cash, stock-based compensation expense. For the year ended December 31, 2015, ACADIA reported a net loss of $164.4 million, or $1.63 per common share, compared to a net loss of $92.5 million, or $0.95 per common share, for 2014. The net losses for 2015 and 2014 included $40.2 million and $16.0 million, respectively, in non-cash, stock-based compensation expense. At December 31, 2015, ACADIA’s cash, cash equivalents, and investment securities totaled $215.1 million compared to $322.5 million at December 31, 2014. Net proceeds of approximately $281.6 million received from ACADIA’s follow-on public offering in January 2016 are not reflected in the balance sheet as of December 31, 2015.

Aegerion Pharmaceuticals Inc (NASDAQ:AEGR) stock is at $3.34, up +4.37 percent from its previous close of $3.20. Its yesterday’s volume was 1.40 million shares in comparison to its usual trading volume of 832,455.00 shares. Previous 5 days graph demonstrated a negative move of -7.48%. Its quarterly performance remained red with the percentage of -53.99, while its year to date performance showed that the stock plunged overall -67.45%.

Aegerion Pharmaceuticals Inc (NASDAQ:AEGR) on April 11, 2016 announced that on March 14, 2016, Aegerion granted options to purchase 75,000 shares of common stock to one new employee; and on April 1, 2016, Aegerion granted options to purchase an aggregate of 57,775 shares of common stock to eight new employees under the inducement stock option program. Each stock option has an exercise price per share equal to $5.43 or $3.55, the closing price of Aegerion’s common stock on March 14 and April 1, respectively; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion’s Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.

Agenus Inc (NASDAQ:AGEN) traded in the range of $4.23 and $4.47 in its previous trading session. The stock recorded the volume of 1.32 million shares so far, in comparison its average daily trading volume of 1.47 million shares. Company’s year to date performance remained declining as it lost almost -6.78%. The stock opened at $4.40 and its closing price for the day was $4.40, up +1.38 percent from its previous close.

Agenus Inc (NASDAQ:AGEN) on March 3, 2016 reported financial results for the fourth quarter and year ended December 31, 2015.

Cash, cash equivalents and short-term investments were $171.7 million as of December 31, 2015.

For the fourth quarter, Agenus reported a net loss attributable to common stockholders of $15.7 million, or $0.18 per share, basic and diluted, compared with a net loss attributable to common stockholders for the fourth quarter of 2014 of $26.0 million, or $0.41 per share, basic and diluted.

The decreased net loss attributable to common stockholders for the quarter ended December 31, 2015, compared to the net loss attributable to common stockholders for the same period in 2014, was due primarily to a $14.8 million decrease in the non-cash charges related to our contingent obligations as well as increased revenue of $6.0 million related to our Incyte collaboration partially offset by increased expenses related to our CPM programs. We recorded non-cash expenses for the quarter ended December 31, 2014 of $6.5 million, due to the fair value adjustment of the contingent purchase price consideration, and $7.7 million related to the fair value adjustment of our contingent royalty obligation. This compares to non-cash income of $623,000 related to the contingent purchase price consideration for the quarter ended December 31, 2015.

For the year ended December 31, 2015, the company incurred a net loss attributable to common stockholders of $88.1 million, or $1.13 per share, basic and diluted, compared with a net loss attributable to common stockholders of $42.7 million, or $0.71 per share, basic and diluted, compared to the same period in 2014.

The increase in net loss attributable to common stockholders for the year ended December 31, 2015, compared to the net loss attributable to common stockholders for the same period in 2014, was primarily due to the advancement of our check point modulator programs, partially offset by the increased revenues of $17.8 million primarily related to our Incyte collaboration; a $13.2 million charge for the acquisition of the SECANT yeast display platform and other license and technology transfer arrangements. We also recorded a total of $13.6 million in non-cash expense for fair value adjustments to our contingent obligations.

During the same period of 2014, the company recorded non-cash expense of $6.7 million due to the fair value adjustment of the contingent purchase price consideration and non-cash income of $2.1 million related primarily to various GlaxoSmithKline vaccine trial results containing QS-21 Stimulon.

 

Comments are closed.